News Quantified

ARTH – arch therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)

Form 10-Q Arch Therapeutics, Inc. For: Mar 31

Form 8-K Arch Therapeutics, Inc. For: Apr 30

Form 8-K Arch Therapeutics, Inc. For: Mar 28

Form 8-K Arch Therapeutics, Inc. For: Mar 12

Form 8-K Arch Therapeutics, Inc. For: Feb 27

Top News Gainers

3/23 Arch Therapeutics Receives Marketing Clearance from the US FDA Related to the AC5® Topical Gel Supply Chain 20.5%

3/4 Arch Therapeutics Novel Self-Assembling Agent for Use in Endoscopic Procedures to be Presented at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2020 Annual Meeting on April 2, 2020 15.9%

11/26 Arch Therapeutics Inc (OTCMKTS: ARTH) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $0.25 price target on the stock. 12.0%

8/14 Examining What Is Next For Arch Therapeutics [Seeking Alpha] 11.2%

4/13 Arch Therapeutics Receives CE Mark Approval for AC5™ Topical Hemostat in Europe 10.5%

11/21 Arch Therapeutics Inc (OTCMKTS: ARTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. 9.4%

11/21 Arch Therapeutics Receives Recommendation That CE Mark Be Granted [Seeking Alpha] 8.1%

12/23 Form 4 Arch Therapeutics, Inc. For: Dec 20 Filed by: SULAT JAMES R 4.7%

10/17 Form 424B5 Arch Therapeutics, Inc. 2.8%

3/2 Arch Therapeutics to Provide Corporate Update at the 2020 LD Micro Virtual Investor Conference 2.6%

Top News Decliners

5/13 Arch Therapeutics, Inc. $2.8 Million Registered Direct Offering -23.3%

10/17 Arch Therapeutics Announces $2.5 Million Registered Direct Offering -20.8%

3/27 Arch Therapeutics Inc (OTCMKTS: ARTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock. -10.4%

3/18 Arch Therapeutics, Inc. to Present at the New York City based Investor Summit on March 25th-26th -6.5%

8/1 Form 10-Q Arch Therapeutics, Inc. For: Jun 30 -4.6%

4/13 Form 424B3 Arch Therapeutics, Inc. -4.5%

11/19 Form 10-K Arch Therapeutics, Inc. For: Sep 30 -2.2%

3/24 Arch Therapeutics Inc (OTCMKTS: ARTH) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -2.0%

1/22 Arch Therapeutics Inc (OTCMKTS: ARTH) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -2.0%

9/3 Arch Therapeutics to Provide Corporate Update at the H.C. Wainwright 21st Annual Global Investment Conference -1.8%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day